{
    "clinical_study": {
        "@rank": "43612", 
        "arm_group": [
            {
                "arm_group_label": "Carfilzomib + ARRY-520", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Carfilzomib", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a Phase 2 study during which patients with advanced multiple myeloma will receive\n      either carfilzomib alone (single-agent) or carfilzomib in combination with investigational\n      study drug ARRY-520. Patients will be followed to determine the effectiveness of both\n      single-agent carfilzomib and carfilzomib + ARRY-520 in treating myeloma. Patients will be\n      allowed to crossover from single-agent carfilzomib to carfilzomib + ARRY-520 if disease\n      progression occurs. Approximately 75 patients from the US will be enrolled in this study."
        }, 
        "brief_title": "A Study of ARRY-520 and Carfilzomib in Patients With Advanced Multiple Myeloma", 
        "condition": "Advanced Multiple Myeloma", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          -  Confirmed multiple myeloma with measurable disease.\n\n          -  Disease refractory to last myeloma regimen.\n\n          -  Patients must have received at least 2 prior treatment regimens, including bortezomib\n             and an IMiD (e.g., lenalidomide, thalidomide, pomalidomide). Induction therapy and\n             stem cell transplant \u00b1 maintenance are to be considered as a single regimen.\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 within 14\n             days prior to first dose of study treatment.\n\n          -  Adequate hematology, liver and renal function laboratory values within 14 days prior\n             to first dose of study treatment.\n\n          -  Additional criteria exist.\n\n        Key Exclusion Criteria:\n\n          -  Prior treatment with carfilzomib, ARRY-520, or any other KSP inhibitor.\n\n          -  Past or current plasma cell leukemia.\n\n          -  Primary amyloidosis (amyloidosis associated with multiple myeloma is allowed).\n\n          -  POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and\n             skin changes).\n\n          -  Ongoing Grade 3 or Grade 4 peripheral neuropathy, or Grade 2 peripheral neuropathy\n             with pain despite appropriate interventions, within 28 days prior to first dose of\n             study treatment.\n\n          -  Autologous or allogeneic stem cell or bone marrow transplant within 3 months prior to\n             first dose of study treatment.\n\n          -  Concomitant malignancies or previous malignancies (other than multiple myeloma) with\n             less than a 2-year disease-free interval at the time of first dose of study\n             treatment. Patients with adequately resected basal or squamous cell carcinoma of the\n             skin, carcinoma in situ of the cervix or breast, or Stage 1 prostate cancer are\n             eligible irrespective of the time of diagnosis.\n\n          -  Known pulmonary hypertension of any severity.\n\n          -  Concurrent cardiac disease that, in the judgment of the Investigator, would make the\n             patient inappropriate for study participation.\n\n          -  Known positive serology for the human immunodeficiency virus (HIV), active hepatitis\n             B and/or hepatitis C.\n\n          -  Acute active infection requiring treatment.\n\n          -  Additional criteria exist."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "75", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01989325", 
            "org_study_id": "ARRAY-520-216"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Carfilzomib + ARRY-520", 
                    "Carfilzomib"
                ], 
                "description": "multiple dose, single schedule", 
                "intervention_name": "Carfilzomib, proteasome inhibitor; intravenous", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Carfilzomib + ARRY-520", 
                "description": "multiple dose, single schedule", 
                "intervention_name": "ARRY-520, KSP(Eg5) inhibitor; intravenous", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Carfilzomib + ARRY-520", 
                    "Carfilzomib"
                ], 
                "description": "as indicated, per the carfilzomib prescribing information", 
                "intervention_name": "Dexamethasone, steroid; oral or intravenous", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Carfilzomib + ARRY-520", 
                "description": "standard of care", 
                "intervention_name": "Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Dexamethasone acetate", 
                "Dexamethasone", 
                "Dexamethasone 21-phosphate", 
                "BB 1101", 
                "Lenograstim"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 20, 2014", 
        "location": [
            {
                "contact": {
                    "email": "rmalone@mednet.ucla.edu", 
                    "last_name": "Rose Malone", 
                    "phone": "310-794-0242"
                }, 
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90095"
                    }, 
                    "name": "UCLA"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "kyoung@rrmg.com", 
                    "last_name": "Kim Young", 
                    "phone": "707-521-3814"
                }, 
                "facility": {
                    "address": {
                        "city": "Santa Rosa", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "95403"
                    }, 
                    "name": "Redwood Regional Medical Group"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "derek.schatz@ucdenver.edu", 
                    "last_name": "Derek Schatz", 
                    "phone": "720-848-0628"
                }, 
                "facility": {
                    "address": {
                        "city": "Aurora", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80045"
                    }, 
                    "name": "University of Colorado Anschutz Medical Campus"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "llhart@flcancer.com", 
                    "last_name": "Lowell Hart, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Fort Myers", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33905"
                    }, 
                    "name": "Florida Cancer Specialists"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "s-duffey@northwestern.edu", 
                    "last_name": "Sarah Duffey"
                }, 
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60611"
                    }, 
                    "name": "Robert H. Lurie Comprehensive Cancer Center of Northwestern University"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mcangany@iupui.edu", 
                    "last_name": "Mary Cangany", 
                    "phone": "317-274-2178"
                }, 
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46202"
                    }, 
                    "name": "Indiana University - Simon Cancer Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "nraje@mgh.harvard.edu", 
                    "last_name": "Dr. Raje", 
                    "phone": "617-724-4000"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02114"
                    }, 
                    "name": "Massachusetts General Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "davisv@karmanos.org", 
                    "last_name": "Valerie Davis", 
                    "phone": "313-576-9370"
                }, 
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48201"
                    }, 
                    "name": "Karmanos Cancer Institute"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "lmcbride@hackensackumc.org", 
                    "last_name": "Laura McBride", 
                    "phone": "551-996-8704"
                }, 
                "facility": {
                    "address": {
                        "city": "Hackensack", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07601"
                    }, 
                    "name": "John Theurer Cancer Center at Hackensack University Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "lendvain@mskcc.org", 
                    "last_name": "Nikoletta Lendvai, MD, PhD", 
                    "phone": "212-639-3368"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10065"
                    }, 
                    "name": "Memorial Sloan Kettering"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mary.tipton@carolinashealthcare.org", 
                    "last_name": "Mary Tipton", 
                    "phone": "704-355-6079"
                }, 
                "facility": {
                    "address": {
                        "city": "Charlotte", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "28204"
                    }, 
                    "name": "Levine Cancer Institute"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Jason Valent", 
                    "phone": "216-444-7923"
                }, 
                "contact_backup": {
                    "last_name": "Cancer Answer Line", 
                    "phone": "1-800-223-2273", 
                    "phone_ext": "47923"
                }, 
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44195"
                    }, 
                    "name": "Cleveland Clinic"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "kathleen.stamper@osumc.edu", 
                    "last_name": "Katie Stamper", 
                    "phone": "614-366-6386"
                }, 
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43210"
                    }, 
                    "name": "Ohio State University"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "andenich@ohsu.edu", 
                    "last_name": "Nicholas Anderson", 
                    "phone": "503-494-3358"
                }, 
                "contact_backup": {
                    "email": "subbiahn@ohsu.edu", 
                    "last_name": "Nan Subbiah", 
                    "phone": "503-494-4603"
                }, 
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97239"
                    }, 
                    "name": "Knight Cancer Institute at Oregon Health & Science University"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "debra.meyer@scresearch.net", 
                    "last_name": "Debra Meyer"
                }, 
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37203"
                    }, 
                    "name": "Sarah Cannon Research Institute"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "anne.roberto@utsouthwestern.edu", 
                    "last_name": "Anne Roberto", 
                    "phone": "214-648-6554"
                }, 
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75390"
                    }, 
                    "name": "Simmons Cancer Center - UT Southwestern Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "nicole.hodge@usoncology.com", 
                    "last_name": "Nikki Hodge"
                }, 
                "facility": {
                    "address": {
                        "city": "Fairfax", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "22031"
                    }, 
                    "name": "Virginia Cancer Specialists"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "pbeal@hsc.wvu.edu", 
                    "last_name": "Patricia Beal", 
                    "phone": "304-293-0609"
                }, 
                "facility": {
                    "address": {
                        "city": "Morgantown", 
                        "country": "United States", 
                        "state": "West Virginia", 
                        "zip": "26506"
                    }, 
                    "name": "WVU - Mary Babb Randolph Cancer Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "cccto@mcw.edu", 
                    "last_name": "Clinical Trials Office", 
                    "phone": "414-805-8900"
                }, 
                "facility": {
                    "address": {
                        "city": "Milwaukee", 
                        "country": "United States", 
                        "state": "Wisconsin", 
                        "zip": "53226"
                    }, 
                    "name": "Medical College of Wisconsin Cancer Center"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "other_outcome": {
            "measure": "Evaluate patient serum levels of alpha 1-acid glycoprotein (AAG) at Baseline and during the treatment period.", 
            "safety_issue": "No", 
            "time_frame": "18 months"
        }, 
        "overall_contact": {
            "last_name": "Array BioPharma Clinical Trial Call Center", 
            "phone": "303-381-6604"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Assess the efficacy of both carfilzomib + study drug and single-agent carfilzomib in terms of progression-free survival.", 
            "safety_issue": "No", 
            "time_frame": "18 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01989325"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Assess the efficacy of both carfilzomib + study drug and single-agent carfilzomib in terms of objective response rate.", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "measure": "Assess the safety of both carfilzomib + study drug and single-agent carfilzomib in terms of adverse events, clinical laboratory tests and electrocardiograms.", 
                "safety_issue": "Yes", 
                "time_frame": "18 months"
            }, 
            {
                "measure": "Characterize the pharmacokinetics (PK) of study drug, carfilzomib and a carfilzomib metabolite in patients treated with carfilzomib + study drug in terms of plasma concentration-time profiles and model-based PK parameters.", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Following crossover from single-agent carfilzomib, assess the efficacy of carfilzomib + study drug in terms of objective response rate.", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "measure": "Following crossover from single-agent carfilzomib, assess the safety of carfilzomib + study drug in terms of adverse events, clinical laboratory tests and electrocardiograms.", 
                "safety_issue": "Yes", 
                "time_frame": "18 months"
            }
        ], 
        "source": "Array BioPharma", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Array BioPharma", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}